The effects of cannabinoids on the brain
Introduction
The hemp plant, Cannabis sativa, has been used for over 4000 years as a recreational drug due to its mind-altering effects. Marijuana, the common name for cannabis, is by far the most commonly used street drug world wide today. However, since the 4th century BC, it also has been employed as a therapeutic drug. No other drug of abuse arouses greater controversy than cannabis. The public debate centers upon the possible legalization of the cannabis use, at least for therapeutic use. There are a number of well-proofed and potential therapeutic actions of cannabinoids, such as antiemetics, analgesia, anticonvulsant action and lowered intraoccular pressure (Hollister, 1986). More recently, its use as an appetite stimulant has been indicated in patients with cachexia or wasting disease such as AIDS (Timpone et al., 1997; Volicer et al., 1997). Unquestionably, existence of psychoactive effects, development of tolerance and the abuse potential of cannabinoids have discouraged their therapeutic use.
Due to the cloning and characterization of specific cannabinoid receptors, the discovery of endogenous cannabimimetic compounds and the availability of selective receptor antagonists, our knowledge of the mechanisms of action of cannabinoids has been greatly increased during the last few years. It is the aim of the present review to present the most important breakthroughs which leads to a better understanding of the actions and risks of cannabinoids. The principle psychoactive component of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC), as well as structurally related cannabinoids are highly lipophilic molecules which exert their central effects by binding at specific membrane receptors, the CB1 cannabinoid receptors. Beside their central effects, cannabinoids possess several peripheral effects, which are believed to be mediated by another type of cannabinoid receptor, the CB2 receptor. Recent advances in characterizing these cannabinoid receptors as well as their signal transduction mechanisms involved will be presented in the present review. A further concern will be the import discovery of the endogenous cannabimimetic system in the brain. The possible physiological role of the two endogenous cannabimimetic compounds, the eicosanoid anandamide (Devane et al., 1992), and the more recently identified 2-arachidonylglycerol (Mechoulam et al., 1995; Stella et al., 1997) will be discussed with regard to a potentially modulation of pain perception and memory.
Section snippets
Active ingredients
The flowering tops and leaves of the plant C. sativa secret a resin containing about 60 terpenophenolic compounds which are called cannabinoids. The highest amount of cannabinoids has been found in the flowering tops, followed by the leaves, whereas only small amounts are found in stem and roots. The seed does not contain any cannabinoids. Preparations, such as marijuana, which is made from dried leaves and tops of the plant, have a lower cannabinoid content than hashish, which is a preparation
Cannabinoid receptors
Since the major psychoactive constituent of marijuana, Δ9-THC, as well as other cannabinoids are highly lipophilic molecules, it was believed for a long time that the effects elicited by these compounds are due to a non-specific interaction with the membrane lipids and alteration of membrane fluidity. Speculation about the cellular actions of cannabinoids was finally resolved when functional inhibition of adenylate cyclase was observed following the addition of Δ9-THC to neuroblastoma cells (
Endogenous cannabinoids
The identification, pharmacological characterization, and localization of specific membrane receptors mediating the central and peripheral effects of the active principle of marijuana, Δ9-THC, and other cannabinoids raised the question about the existence of endogenous cannabinoid agonists to which the receptors must respond, similar to the existence of endogenous ligands for the opiate receptors. The only endogenous substances isolated and characterized so far that are capable of mimicking the
Modulation of neuronal activity in distinct brain region
This section focuses on the effects induced by cannabinoids via modulation of three main transmitters, glutamate, dopamine, and GABA, in such brain regions known to possess a high density of CB1 receptors and to be involved in some of the characteristic effects of marijuana.
Future directions
Cannabis does not appear to be a harmless recreational drug. Acute intoxication is characterized by euphoria, loss of short-term memory, stimulation of the senses, and impaired linear thinking. Depersonalization and panic attacks are adverse effects. Increased heart rate, reddened conjunctivae and immunosuppression are common peripheral effects. Chronically consumed high doses may cause impairment of cognitive abilities that are appear to be long-term, or even persistent.
The public debate
Unlinked references
Caput and Ferrara, 1995; Pertwee and Ross, 1991: AUTHOR—NOT CITED IN TEXT; PLEASE INSERT.
References (224)
- et al.
Neurobiology of marijuana abuse
Trends Pharmacol. Sci.
(1992) Functional characteristics of the midbrain periaqueductal gray
Prog. Neurobiol.
(1995)- et al.
Acute effects of marijuana on cognition: Relationships to chronic effects and smoking techniques
Pharmacol. Biochem. Behav.
(1992) - et al.
Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells
J. Biol. Chem.
(1995) - et al.
Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain
Eur. J. Pharmacol.
(1997) - et al.
Chronic marijuana smoke alters alveolar macrophage morphology and protein expression
Pharmacol. Biochem. Behav.
(1991) - et al.
Effects of anandamide on cannabinoid receptors in rat brain membranes
Biochem. Pharmacol.
(1994) - et al.
Chronic cannabinoid, CP-55 940, administration alters biotransformation in the rat
Eur. J. Pharmacol.
(1996) - et al.
Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomobility and hypothermia in-vivo in rodents
Pharmacol. Biochem. Behav.
(1993) - et al.
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
Biochem. Pharmacol.
(1993)